



Nicox's shareholders approve acquisition of Acix Therapeutics, Inc.

October 22, 2014

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that its shareholders voted to approve the acquisition of Acix Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company, at the General Meeting held today October 22, 2014, with more than 97% of votes in favour. The transaction is expected to be completed within the next few days, following the completion of certain legal conditions and formalities. All the other resolutions submitted to the General Meeting were also approved.

The acquisition of Acix represents a significant step forward in Nicox's strategy of creating an international ophthalmic company and will significantly broaden and strengthen Nicox's therapeutic development pipeline. Acix's therapeutic pipeline includes:

- AC-170 for allergic conjunctivitis, which has completed two phase 3 trials and for which Nicox plans to seek a pre-NDA meeting with the Food and Drug Administration (FDA) by Q1 2015 before the submission of a New Drug Application (NDA);
- AC-155 for post-operative ocular inflammation and pain, which is expected to enter phase 2 studies in 2015, pending FDA agreement.

Upon completion of the acquisition, Nicox will exchange 20,627,024 newly issued Nicox shares for 100% of Acix's shares. The transaction also includes contingent value rights giving right to shares for a potential additional value of up to \$55 million, based on the potential US FDA approval(s) of AC-170 and of two additional undisclosed products within a pre-determined period.

Nicox's shareholders also approved the nomination to Nicox's Board of Directors of Les Kaplan, PhD, Executive Chairman of Acix Therapeutics, Inc. and former Executive Vice President and President, Research and Development of Allergan, Inc.

For more information, see the [Nicox press release dated July 2, 2014](#) and the ['Document E'](#) registered with

the French *Autorité des Marchés Financiers* (AMF) on September 30, 2014 (E.14-060) (in French, available on Nicox's website www.nicox.com in the 'Investor Information' / 'Shareholder meetings' section).

About Nicox



Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is VESNEO (latanoprostene bunod), a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in: the 4th chapter of the "Document de référence, rapport financier annuel et rapport de gestion 2013" filed with the French Autorité des Marchés Financiers (AMF) on April 2nd, 2014; the "Rapport semestriel financier et d'activité au 30 juin 2014"; the 5th chapter of the "Actualisation du Document de Référence 2013" filed with the AMF on September 30, 2014 (D. 14-0271-A01); and the section B of the 'Document E' registered with the AMF on September 30, 2014 (E.14-060). All these documents are available on Nicox's website (www.nicox.com).

Contacts



Nicox **Gavin Spencer | Executive Vice President Corporate Development**
+33 (0)4 97 24 53 00 | communications@nicox.com

Media Relations

United Kingdom **Jonathan Birt**
+44 7860 361 746 | jonathan.birt@ymail.com

France **Caroline Courme | Communication Manager**
+33 (0)4 97 24 53 43 | courme@nicox.com